Skip to content

Vir Biotechnology

US · VIR #2824 by market cap Listed 2019
8.39 -0.48 -5.41%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Rating change
    BofA Securities Maintains Vir Biotechnology(VIR.US) With Buy Rating, Raises Target Price to $17
    Market Newswire · 2026/11/6
  • Rating change
    BofA Securities Maintains Vir Biotechnology(VIR.US) With Buy Rating, Cuts Target Price to $15
    Market Newswire · 2026/8/8
  • Company notice
    Vir Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director Hatfield Jeffrey S.
    SEC · 2026/5/29
  • Company notice
    Vir Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director Hatfield Jeffrey S.
    SEC · 2025/6/3
  • Rating change
    Vir Biotechnology Is Maintained at Buy by HC Wainwright & Co.
    Dow Jones · 2026/10/7
  • Company notice
    Vir Biotechnology | 4: Statement of changes in beneficial ownership of securities-Officer HANLY ANN M.
    SEC · 2025/2/26
  • Rating change
    Needham Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $18
    Market Newswire · 2026/9/29
  • H.C. Wainwright Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $22
    Market Newswire · 2026/11/10
  • Rating change
    Leerink Partners Maintains Vir Biotechnology(VIR.US) With Buy Rating, Cuts Target Price to $17
    Market Newswire · 2026/9/30
  • Here's What Analysts Are Forecasting For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Third-Quarter Results
    Simply Wall St · 2026/11/7
  • Rating change
    HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $22
    Benzinga · 2026/10/7
  • Company notice
    Vir Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director Hatfield Jeffrey S.
    SEC · 2024/6/4
  • Rating change
    H.C. Wainwright Maintains Vir Biotechnology(VIR.US) With Buy Rating, Raises Target Price to $22
    Market Newswire · 2026/10/7
  • Rating change
    A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $11.77 to $30
    Market Newswire · 2026/11/6
  • A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $22 to $30
    Market Newswire · 2026/11/11
  • Barclays Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $30
    Market Newswire · 2026/11/12
  • Company notice
    Vir Biotechnology | 4: Statement of changes in beneficial ownership of securities-Officer HANLY ANN M.
    SEC · 2024/4/3
  • Rating change
    H.C. Wainwright Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $20
    Market Newswire · 2026/9/22
  • U.S. Stock Market Watch: Vir Biotechnology Plunges Over 14% in Pre-Market Trading as Share Offering Dilutes Float by ~11% and Prices at a Discount
    Gelonghui Finance · 2026/11/13
  • Rating change
    Vir Biotechnology Price Target Raised to $22.00/Share From $20.00 by HC Wainwright & Co.
    Dow Jones · 2026/10/7
  • Rating change
    A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $18 to $30
    Market Newswire · 2026/8/6
  • Rating change
    A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $15 to $30
    Market Newswire · 2026/8/7
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), Sutro Biopharma (STRO) and Ardent Health Partners, Inc. (ARDT)
    TipRanks · 2026/6/11
  • Rating change
    Morgan Stanley Maintains Vir Biotechnology(VIR.US) With Buy Rating, Raises Target Price to $27
    Market Newswire · 2026/6/11
  • Rating change
    Leerink Partners Maintains Vir Biotechnology(VIR.US) With Buy Rating
    Market Newswire · 2026/5/27

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Vir Biotechnology discussion 0 comments

Add a comment